Monoclonal Gammopathy of Undetermined Significance (MGUS)
8
6
6
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells
The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH